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Chromosomal aneuploidy and specific gene muta-
tions are recognized early hallmarks of many onco-
genic processes. However, the net effect of these
abnormalities has generally not been explored. We
focused on transient myeloproliferative disorder
(TMD) in Down syndrome, which is characteristically
associatedwith somaticmutations inGATA1. To bet-
ter understand functional interplay between trisomy
21 and GATA1 mutations in hematopoiesis, we
constructed cellular disease models using human
induced pluripotent stem cells (iPSCs) and genome-
editing technologies. Comparative analysis of these
engineered iPSCs demonstrated that trisomy 21 per-
turbed hematopoietic development through the
enhanced production of early hematopoietic progen-
itors and the upregulation of mutated GATA1, result-
ing in the accelerated production of aberrantly
differentiated cells. These effects were mediated by
dosage alterations of RUNX1, ETS2, and ERG, which
are located in a critical 4-Mb region of chromosome
21. Our study provides insight into the genetic syn-
ergy that contributes to multi-step leukemogenesis.
INTRODUCTION
Down syndrome (DS; trisomy 21) is the most common chromo-
somal aneuploidy, caused by the presence of three copies of1228 Cell Reports 15, 1228–1241, May 10, 2016 ª 2016 The Authors
This is an open access article under the CC BY license (http://creativehuman chromosome 21 (HSA21). Among various medical symp-
toms, DS patients have an increased likelihood of certain he-
matopoietic abnormalities, including transient myeloproliferative
disorder (TMD) and leukemia (Roy et al., 2009). TMD involves the
clonal proliferation of immature megakaryoblasts, which typi-
cally occurs in 10% of infants with DS. In addition, 20%–30%
of TMD survivors progress to acute myeloid leukemia (ML-DS;
myeloid leukemia associated with Down syndrome, also called
DS-AMKL, M7) within 4 years (Pine et al., 2007). Both DS-TMD
andML-DS cells harbor somatic mutations inGATA1, a hemato-
poietic transcription factor located on the X chromosome, which
result in loss of the full-length protein product and the exclusive
production of a short GATA1 variant (GATA1s) (Hitzler and Zipur-
sky, 2005). Except for some rare hereditary diseases (Hollanda
et al., 2006; Sankaran et al., 2012), somatically acquired
GATA1s-producing mutations are found solely in cells that are
trisomic for chromosome 21. These two factors (i.e., a single ac-
quired GATA1 mutation and constitutive trisomy 21) are now
considered necessary and sufficient to cause TMD (Yoshida
et al., 2013). Thus, the distinctive features of DS, TMD, and
ML-DS provide ideal models to study the multistep process of
leukemia caused by aneuploidy and specific gene mutations.
Here, we established systematic and strategically designed
cellular disease models by combining patient-derived human
induced pluripotent stem cells (hiPSCs), genome-editing tech-
nologies, and chromosome engineering techniques. 20 types
(and more than 40 clones) of hiPSCs were generated and sub-
jected to hematopoietic differentiation to explore the synergistic
interaction between GATA1 mutation and gene-dosage effects
of trisomy 21 in hematopoiesis (Figures 1 and 6A). Constitutive
trisomy 21 not only accelerates the production of hematopoieticcommons.org/licenses/by/4.0/).
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Figure 1. Human iPSC-Based Modeling of Hematopoietic Abnormalities in DS
Schematic overview depicting the strategy to generate twelve types of genome-edited iPSC lines for in vitro diseasemodeling. (Left, case 1) First, Di21-GATA1wt,
Tri21-GATA1wt, and Tri21-GATA1s iPSC lines were directly generated from human blood samples using Sendai virus (SeV). Second, GATA1KO lines were
generated fromDi21- and Tri21-GATA1wt iPSC lines using a TALEN and donor DNA (Di21- and Tri21-GATA1KO, respectively; arrow). Third, a 17-bp deletion was
introduced into the Di21-GATA1wt iPSC line using a Platinum TALEN (Di21-GATA1s; dotted arrow). Fourth, a 4-Mb region was deleted from a single chromosome
21 in the Tri21-GATA1wt iPSC line (Partial-Tri21-GATA1wt; bold arrow). Finally, the Partial-Tri21-GATA1s iPSC line was generated using a Platinum TALEN
(dotted arrow). (Right, case 2) Additional Tri21-GATA1wt and -GATA1s iPSC lines (case2-Tri21-GATA1wt and -GATA1s) were generated from another DS patient
(case 2), and isogenic disomy iPSC lines were obtained by spontaneous loss of chromosome 21 (case2-Di21-GATA1wt and -GATA1s; upward bold arrow).progenitors, which leads to enhanced multilineage differentia-
tion, but also upregulates GATA1s expression, giving rise to
the excessive generation of abnormal megakaryoblasts. We
succeeded in isolating a 4-Mb region critical for hematopoietic
defects in DS and identified three genes, RUNX1, ETS2, and
ERG, as key molecules involved in an interconnected regulatory
network. The results demonstrate synergistic effects of aneu-
ploidy and a specific gene mutation on the leukemogenesis.
RESULTS
Generation of Systematic Cellular Disease Models
Incorporating Trisomy 21 and GATA1 Mutations
Our first aim was to establish an iPSC-based in vitro model sys-
tem that would enable us to investigate the interaction between
GATA1mutations and trisomy 21 in TMD. For this purpose, mul-
tiple iPSC lines based on the chromosome 21 copy number (dis-
omy, Di; or trisomy, Tri) and variations due to GATA1 mutation
(no mutation, GATA1wt; short-form mutation, GATA1s; and
knockout mutation, GATA1KO) were designed (Figure 1). We
identified two newborn male patients with DS-TMD, who typi-
cally presented with constitutive trisomy 21, high white blood
cell counts, hepatomegaly, and pericardial/pleural/ascitic effu-
sions (cases 1 and 2; Table S1). Introduction of reprogramming
factors into peripheral blood cells derived from case 1, which
included cell types with and without GATA1 mutations, resulted
in the establishment of two different isogenic iPSC lines: onewith
normal GATA1 (Tri21-GATA1wt) and the other with the GATA1s-
producing mutation (Tri21-GATA1s). All iPSC clones in the Tri21-
GATA1s line from case 1 shared the same 16-bp duplication inexon 2 of GATA1, resulting in a premature stop codon in
the N-terminal activation domain (Figure 2A). No acquired muta-
tions were found in the protein-coding sequences of RAD21,
CTCF, or EZH2, which are representative mutational targets in
ML-DS (Yoshida et al., 2013). A control iPSC line with a normal
karyotype and wild-type GATA1 were also generated from
cord blood mononuclear cells obtained from a euploid male
subject (Di21-GATA1wt). To generate iPSC lines carrying a
targeted GATA1 gene mutation, the most active pair of tran-
scription activator-like effector nucleases (TALENs), which
recognize unique sequences in the proximity of the second
ATG in exon 3 of GATA1 (Figures 2B and S2A), and a targeting
donor construct were introduced into the Di21- and Tri21-
GATA1wt iPSC lines. This procedure resulted in the generation
of Di21-GATA1KO and Tri21-GATA1KO iPSC lines, respectively
(Figures 2C and 2D).
To generate the Di21-GATA1s iPSC line, we introduced a
highly active Platinum TALEN and performed one round of
sib-selection (Figures 2G, S2B, S2C, S2E, and S2F see also
Figure S5I, method 1) (Sakuma et al., 2013). Di21- and Tri21-
GATA1s lines expressed only short-form products accompanied
by unstable transcripts leading to nonsense-mediated decay
(NMD), confirming the absence of full-length products (Fig-
ure 2H). Interestingly, GATA1s expression was evidently higher
in Tri21-GATA1s cells than in Di21-GATA1s cells, indicating the
direct influence of trisomy 21 on GATA1s expression (Figures
2H and S2H; see also Figures 4I and S7). In contrast, neither
GATA1 nor GATA1s transcripts were detected in Di21- and
Tri21-GATA1KO lines. All iPSC clones exhibited a typical
morphology and normal euploidy or trisomy 21 karyotypesCell Reports 15, 1228–1241, May 10, 2016 1229
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(Figures S2D and S2G). The assessments of pluripotency and
the differentiation ability of iPSC lines are described in Figure S1.
Trisomy 21 Promotes Early Hematopoietic Commitment
and Multilineage Differentiation: Comparison between
Di21- and Tri21-GATA1wt iPSCs
Several reports have demonstrated that trisomy 21 augments
fetal hematopoiesis (Chou et al., 2012; Maclean et al., 2012).
To confirm these findings and further examine the effect of
trisomy 21 in our models, Di21- and Tri21-GATA1wt iPSCs
were differentiated into a hematopoietic lineage by generating
embryoid bodies (EBs) using published protocols with some
modifications (Figure 3A) (Grigoriadis et al., 2010; Ng et al.,
2008). qRT-PCR analysis of stage-specific b-like globins in day
10 EBs showed predominant g-globin expression, suggesting
that our differentiation protocol reflected fetal hematopoiesis
(Figure 3B). We first examined the early hematopoietic develop-
mental stage, in which hematopoietic stem cells (HSCs) emerge
from a specialized subset of vascular endothelial cells (hemo-
genic endothelium). Previous reports have shown that the human
pluripotent stem cell-derived KDR+CD31+ cell population ap-
pears at the beginning of the hematopoietic development and
has the potential to generate blast colonies that display both he-
matopoietic and endothelial cells (Choi et al., 2012). There was
no significant difference in the KDR+CD31+ cell population be-
tween Di21- and Tri21-GATA1wt iPSC-derived EBs (Figure 3C).
However, the proportion of CD43+ cells in the CD34+CD38Lin
fraction, representing putative hematopoietic progenitors, was
significantly increased in the Tri21-GATA1wt line compared
with that in Di21-GATA1wt line (Figures 3D, S3A, and S3B) (Vo-
dyanik et al., 2006). This result suggests that trisomy of chromo-
some 21 accelerates the early stage of hematopoiesis, leading to
the increased production of committed hematopoietic progeni-
tors. Reflecting this enhanced commitment to a hematopoietic
lineage, Tri21-GATA1wt iPSCs gave rise to erythroid-lineage
cells (CD235/glycophorin A) at a rate more than double that for
Di21-GATA1wt cells (Figures 3E and S3C). A similar increase in
the CD33+ fraction, which reflects myeloid cells and their pro-
genitors, was detected in trisomic cells (Figure 3F). This patternFigure 2. Gene Editing of GATA1 by TALEN-Mediated HDR and NHEJ
(A) GATA1 sequence data from the Tri21-GATA1s iPSC line (case 1; 16-bp dupli
(B) Schematic representation of the GATA1-targeting strategy by homology-dire
targeting vector containing the puromycin-resistance gene and800-bp homolog
restriction enzyme sites (S, SpeI; H, HincII; and P, PvuII), TALEN target site 1 (v
indicated.
(C and D) Southern blot analysis of iPSC lines before (Di21- and Tri21-GATA1wt) a
internal probe (probe 2; D). Expected fragment sizes: probe 1 (SpeI/HincII digest)
allele, no band; targeted allele, 3.59 kb; random integration, 2.6 kb.
(E) Schematic representation of theGATA1-modification strategy by non-homolog
TALEN target site 2 (vertical white arrow), and PCR primer sites are indicated.
(F) PCR mutation analysis of the genomic GATA1 locus in TALEN-injected Di21-
(BamHI) 1,231 bp, (+BamHI) 560/513/158 bp; Di21-GATA1s (+BamHI) 1,073 (+in
(G) GATA1 sequence data for the Di21-GATA1s iPSC line (17-bp deletion). Micro
(H) Representative photomicrographs showing RT-PCR products for GATA1 and
from day 8 EBs; left). Fragment sizes: Di21- and Tri21-GATA1wt, 359/120 bp; Di2
Tri21-GATA1s (16-bp duplication), 375/120 bp. A schematic of each mRNA w
products is shown on the right. NMD, nonsense-mediated decay. Note that DNA
the expected gene editing.
See also Figures S1 and S2.was even more apparent in a methylcellulose colony-forming
assay with Tri21-GATA1wt iPSCs generating more than 5-fold
the numbers of multilineage colonies of CFU-G/GM/M, -E,
and -GEMMcells (Figures 3G and S3D). Moreover, themegakar-
yocyte colony-forming assay showed that trisomy 21 iPSC lines
generated over 5-fold more megakaryocyte colonies than
disomic iPSCs (Figures 3H and S3E). These results are consis-
tent with the increased number of hematopoietic progenitor cells
in Tri21-GATA1wt iPSC lines.
Full-Length GATA1 Is Indispensable for Erythropoiesis:
Comparison among GATA1wt, GATA1s, and GATA1KO
iPSCs
The acquisition of a somatic short-formmutation inGATA1 is the
second step of leukemogenesis in DS, which impairs the pro-
duction of mature erythrocytes during erythropoiesis (Byrska-
Bishop et al., 2015). To further address whether this effect is
due to the presence of the short-form protein or the absence
of the full-length form, we examined the erythropoiesis of the
GATA1wt, GATA1s, and GATA1KO iPSCs. In contrast to the
clear production of CD235+ erythroid cells by GATA1wt-contain-
ing iPSC lines, clones lacking the full-length form of GATA1
(i.e., GATA1s and GATA1KO iPSC lines) exhibited severely
impaired erythrocytes, suggesting that the normal function
of full-length GATA1 is indispensable for erythrocyte develop-
ment, regardless of the number of copies of chromosome 21
(Figure 3E).
Short-Form GATA1 Mutation Causes Aberrant
Differentiation of Megakaryocytes
A clinical characteristic of TMD is the abnormal proliferation of
megakaryoblasts (Roy et al., 2009). We thus examined the func-
tional effects of GATA1s and GATA1KO on megakaryopoiesis.
A two-step protocol, in which EB formation was followed by
coculture with MS5 (murine stromal) or AFT024 (murine fetal liver
stromal) cells, generated highly consistent results in terms of the
later differentiation stages (Figure 4A). In this protocol, on day 15,
the numbers of CD34+ cells were significantly increased in
trisomic lines compared with those in disomic ones, which isin Human iPSCs
cation). The asterisk indicates the premature stop codon.
cted repair (HDR). Top: structure of the endogenous GATA1 gene. Middle: the
y arms. Bottom: schematic of the targeted GATA1 locus. Exons (black boxes),
ertical white arrow), and the probe for Southern blot analysis (gray bars) are
nd after (Di21- and Tri21-GATA1KO) targeting using a 50 probe (probe 1; C) and
wild-type allele, 4.9 kb; targeted allele, 3.3 kb. Probe 2 (PvuII digest) wild-type
ous end-joining (NHEJ). Exons (black boxes), restriction enzyme sites (BamHI),
GATA1wt iPSCs (+/BamHI digest). Expected fragment sizes: Di21-GATA1wt
del)/158 bp. A 17-bp deletion by NHEJ resulted in production of 1,056/158 bp.
homologies flanking the double-strand break are underlined.
b-actin (ACTB) mRNAs in each human iPSC line (CD34+CD38 cells isolated
1- and Tri21-GATA1KO, no band; Di21-GATA1s (17-bp deletion), 342/120 bp;
ith the PCR primers, corresponding amplicon lengths, and resulting protein
fragments in each band were extracted from the gel and sequenced to confirm
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Figure 3. Effects of Trisomy 21 and GATA1Mu-
tation on Multilineage Hematopoiesis
(A) Schematic of the hematopoietic differentiation
protocol employing EBs.
(B) Globin expression (relative to GAPDH) in day 10
EBs (n = 3 per clone).
(C) Percentage of cells derived from day 8 EBs that
were positive for KDR and CD31 (n = 3 per clone).
(D) Percentage of CD43-positive cells in CD34+
CD38Lin cells derived from day 8 EBs (n = 37 per
clone). Data for the Partial-Tri21-GATA1wt iPSC line
will be described with the related results in Figure 5.
(E and F) Percentages of (E) CD235- and (F) CD33-
positive cells derived from day 12 EBs, respectively
(n = 38 per clone).
(G) Absolute colony number in methylcellulose cul-
tures from day 10 EBs (n = 3 per clone).
(H) Number of CFU-megakaryocyte (Mk) colonies
derived from day 10 EBs in MegaCult-C medium (n = 3
per clone).
Error bars represent SEM. p values were determined
by the Student’s t test or Mann-Whitney U test.
*p < 0.05, **p < 0.01. See also Figure S3.
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consistent with the enhanced early hematopoiesis in trisomy 21
(Figure 4B).
The development of hematopoietic progenitors into themega-
karyocytic lineage is characterized by the expression patterns of
CD34 and CD41, which are defined by the cell types or differen-
tiation protocols (Pick et al., 2013; Schipper et al., 2003). Di21-
and Tri21-GATA1wt iPSC lines produced sufficient numbers of
CD34CD41+ cells, which were generally larger than CD34+
CD41 hematopoietic progenitors and had one or a few nuclear
lobes, representing promegakaryocytes or immature megakar-
yocytes. Consistent with the results from the megakaryocyte
colony-forming assay, Tri21-GATA1wt iPSCs produced more
CD34CD41+ cells than Di21-GATA1wt iPSCs (Figure 4C–4E).
In contrast, both Tri21- and Di21-GATA1s iPSC lines generated
a significantly larger population of CD34+CD41+ double-positive
cells, which was remarkably small in the presence of the full-
length GATA1 form. This cell fraction was occupied by the
dysplastic form of megakaryocytes with multiple separate
nuclei, which are characteristically found in the bone marrow
of patients with myelodysplastic syndrome (Figures 4C–4F and
S4A) (Bhasin et al., 2013). CD34+CD41+ cells were similarly
generated in Di21- and Tri21-GATA1KO iPSC lines to some
extent, but the cell population was smaller than in the Di21-
and Tri21-GATA1s iPSC lines. A previous report demonstrated
the dominant action of GATA1s on the megakaryopoiesis in mu-
rine fetal liver cells (Li et al., 2005). On the other hand, loss of the
full-length form of GATA1 has been reported to cause the exces-
sive proliferation of megakaryocytes (Muntean and Crispino,
2005). To study whether this aberrant megakaryopoiesis is
caused by the direct action of GATA1s, the loss of function of
the full-length form of GATA1, or both, we forced GATA1s
expression in the Di21-GATA1wt iPSC line by lentiviral transduc-
tion. This forced expression of GATA1s led to a significant
increase in the production of CD34+CD41+ cells in the Di21-
GATA1wt iPSC line, but the cell number was low compared
with the number in the Di21-GATA1s iPSC line (Figures 4G and
S4B). This suggests the dominant accelerating effect of GATA1s
and the possible suppressive effect of full-length GATA1 on the
generation of CD34+CD41+ cells. There were no significant dif-
ferences in annexin V-positive cell numbers between trisomic
iPSC lines (Figure 4H). These results indicate that mutant
GATA1s perturbs proper megakaryocyte differentiation andFigure 4. Synergistic Interaction between Trisomy 21 and GATA1 Muta
(A) Schematic of the two-step differentiation protocol using a co-culture system
(B) Average number of total CD34+ cells per well on day 15 (n = 3 per line). Histogra
GATA1s iPSC line are described with the related results in Figure 5.
(C) Representative flow cytometric analysis showing CD34+CD41, CD34+CD41+
(D)RepresentativemicrophotographsofMay-Gr€unwald-Giemsa-stained cytospins
(E) Absolute number of CD34+CD41+ cells (dark color; lower column) and CD34
(F) Ratio of CD34+CD41+ cells to the total CD41+ cell number on day 15.
(G) Upper: semiquantitative RT-PCR analysis of GATA1s and b-actin mRNA in le
per well on day 15 (n = 3 per line).
(H) Percentage of annexin V+ cells from CD34+CD38 progenitors (n = 3 per line
(I) Semiquantitative RT-PCR analysis of GATA1 and b-actin mRNA in CD34+CD38
iPSC lines. A total of 30- and 35-PCR cycles were performed. Expected PCR fra
(J) Ratio of CD34+CD41+ cells to the total CD41+ cell number on day 15 (n = 3 p
Error bars represent SEM. p values were determined by the Student’s t test to co
independent groups. *p < 0.05, **p < 0.01. See also Figure S4.
1234 Cell Reports 15, 1228–1241, May 10, 2016that the production of aberrant megakaryoblasts can be further
accelerated on a trisomy 21 background.
Isogenic hiPSC Lines Derived from Another Patient
Reproduce the Effect of GATA1s on Megakaryocyte
Differentiation
In our established iPSC lines, the genome-edited disomic or
trisomic iPSC clones shared a genetic background, except for
the GATA1 gene. However, because Di21- and Tri21-GATA1wt
iPSCs were derived from different individuals (non-DS and DS)
and not genetically matched, it is difficult to attribute the
observed phenotype solely to the chromosomal abnormality.
Therefore, we generated additional trisomic and isogenic
disomic iPSC lines from a different male DS-TMD patient
(case 2) (see Figure 1, right; spontaneous loss). Two iPSC lines
(case2-Tri21-GATA1wt and -GATA1s) were simultaneously
generated from cord blood samples from case 2. Over several
passages, some trisomic cells spontaneously lost one copy of
chromosome 21, giving rise to disomic cells (case2-Di21-
GATA1wt and -GATA1s), which were isogenic except for
chromosome 21 (Figure S4C). Case2-Di21- and case2-Tri21-
GATA1s iPSC lines shared a GATA1 point mutation in the 50
splice site of intron 2, resulting in the loss of normal expression
of the full-length transcript (Figures 4I and S4D). During mega-
karyocyte differentiation, both case2-Di21- and case2-Tri21-
GATA1s iPSCs appeared to produce aberrant CD34+CD41+
megakaryoblasts (Figure 4J), which was consistent with the
data obtained from case 1. Taken together, these findings
demonstrate that the expression of GATA1s and the absence
of the full-length form lead to the suppression of normal mega-
karyocyte maturation and increased production of aberrant
megakaryoblastic cells.
Generation of Partial Trisomy 21 iPSCs by Targeted
Deletion of a 4-Mb Region on Chromosome 21
During gene expression analysis of hematopoietically differenti-
ated trisomy 21 iPSCs, we noticed that a group of genes on chro-
mosome 21 showed higher than expected expression (1.5-fold)
and formed a cluster in the restricted region (an4-Mb segment
between RUNX1 and ETS2) (Figure S5A). Thus, we determined
whether this region is critical for the hematopoietic defects in
DS by generating a partial trisomy iPSC line in which this 4-Mbtion during Megakaryocyte Differentiation
with MS5 or AFT024 cells.
m bar colors correspond to the iPSC lines in Figure 1. Data for the Partial-Tri21-
, and CD34CD41+ cells on day 15. Total cell counts in each gate are indicated.
ofCD34+CD41+ andCD34CD41+ cells onday 15. Scalebars represent 25mm.
CD41+ cells (light color; upper column) per well on day 15 (n = 3 per line).
ntivirus-transduced iPSCs. Lower: average number of total CD34+CD41+ cells
).
 progenitors isolated from day 8 EBs formed by case2-Di21- and case2-Tri21-
gment sizes: GATA1wt, 359 bp; GATA1s, 120 bp.
er line).
mpare two independent groups, or Dunnett’s or Steel’s test to compare three
region was deleted from a single copy of chromosome 21, result-
ing in reversion to disomy in this deleted region alone. If these
partial trisomy 21 iPSCs lost their pathological features, the
phenotype could be attributed to this 4-Mb region. Two loxP-
flanked cassettes were introduced sequentially into single alleles
of the RUNX1 and ETS2 genes located on the same chromo-
some in Tri21-GATA1wt iPSCs. The resultant double-targeted
clones were subjected to Cre recombinase-mediated excision
(Figures 5A and S5B–S5G). Deletion of the 4-Mb region was
confirmed by comparative genomic hybridization (CGH) anal-
ysis, DNA fluorescent in situ hybridization, and gene expression
analysis (Figures 5B, 5F, and S5H) (hereafter referred to as
Partial-Tri21-GATA1wt iPSCs).
The 4-Mb Region on Chromosome 21 Is Critical for
Hematopoiesis in DS
To assess the role of this 4-Mb region in the hematopoietic ab-
normalities of DS, we differentiated the Partial-Tri21-GATA1wt
iPSC line into hematopoietic lineages. Notably, the proportion
of CD43+ cells in the CD34+CD38Lin fraction was decreased
dramatically in Partial-Tri21-GATA1wt iPSCs compared with
that in the Tri21-GATA1wt line (Figure 3D). Similarly, the number
of both CD235+ and CD33+ cells produced by Partial-Tri21-
GATA1wt iPSCs was significantly lower than that produced by
Tri21-GATA1wt, which returned to the normal level observed
in the Di21-GATA1wt iPSC line (Figures 3E and 3F). These find-
ings suggest that the accelerating effect on the production of
early hematopoietic precursors and subsequent multilineage he-
matopoiesis in trisomy 21 requires the extra copy of this 4-Mb
region.
Trisomy of the 4-Mb Region on Chromosome 21
Perturbs Megakaryocyte Development via GATA1s
Upregulation
We introduced the short-form mutation of GATA1 into Partial-
Tri21-GATA1wt iPSCs using a Platinum TALEN (Figures S2C
and S5I, method 2). Importantly, the generation of aberrant
CD34+CD41+ megakaryoblastic cells was markedly decreased
in the Partial-Tri21-GATA1s iPSC line compared with that in
the Tri21-GATA1s iPSCs line, indicating that trisomy of this
4-Mb region plays a critical role in abnormal megakaryocyte dif-
ferentiation (Figures 5C and S5J).
GATA1s expression in CD34+CD38 cells on day 8 EBs was
increased significantly in trisomy 21 cells compared with that in
disomy cells at in both transcriptional (Figure 5E) and protein
levels (Figure S2H). This upregulation of GATA1s was similarly
observed in the case2-Tri21-GATA1s iPSC line compared with
that in the case2-Di21-GATA1s iPSC line (Figures 4I and S5K).
Because the latter was derived from the former by the sponta-
neous loss of an extra copy of chromosome 21, the GATA1
loci of these two isogenic iPSC lines have the same mutation,
ruling out the possibility that the upregulation of the short form
was due to different types of mutation in GATA1 (Kanezaki
et al., 2010). Importantly, GATA1s expression was markedly
decreased in Partial-Tri21-GATA1s iPSCs (Figures 5D, 5E, and
S2H), with the cell numbers of CD34+CD41+ double-positive
megakaryoblasts appearing to correlate with GATA1s expres-
sion levels (Figure 5C). These results strongly suggest thattrisomy of the 4-Mb region causes megakaryoblast hyperprolif-
eration via GATA1s upregulation in a dose-dependent manner.
To verify this hypothesis, we forced the expression of GATA1s
in the Partial-Tri21-GATA1s iPSC line by lentiviral transduction.
As expected, this enhanced GATA1s expression resulted in a
significant increase in the production of abnormal CD34+
CD41+ megakaryoblasts, which returned to a level similar to
that observed in the Tri21-GATA1s iPSC line (Figure 5C). The
fraction of mature CD34CD41+megakaryocytes was increased
slightly, but was far from the level observed in the Di21-GATA1s
iPSC line (Figure S5J).
RUNX1, ETS2, and ERG are Critical Regulators of
Hematopoietic Abnormalities in Trisomy 21
The 4-Mb region on HSA21 contains 20 protein-coding genes
and several noncoding RNA genes (Table S2). To identify key
molecules with copy-number alterations that are specifically
associated with hematopoietic abnormalities, we further pre-
pared several genome-edited trisomy 21 iPSC lines, in which
candidate genes were targeted only in a single chromosome,
with or without GATA1s mutation. Because our data suggested
that trisomy 21 had a significant effect on the generation of he-
matopoietic progenitors, we focused on RUNX1, an essential
regulator in this process, and its cofactors ETS2 and ERG.
The resultant alleles are referred to as RUNX1+/+/m (R+/+/m),
ETS2+/+/m (Et+/+/m), and ERG+/+/m (Er+/+/m) (Figures 6A and
S6A). Note that trisomy of HSA21 was conserved in these cells,
and the dosages of the target genes were restored to normal
(i.e., two copies). The loss of one copy of the RUNX1 gene
(R+/+/m-Tri21-GATA1wt and -Tri21-GATA1s) was sufficient
to cancel the accelerating effect on early hematopoietic spe-
cification (CD43+ cells) and later differentiation (CD235+ and
CD33+ cells) stages caused by trisomy 21 (Figures 6B,
S6B, and S6C). Double targeting of RUNX1 and ETS2, or
RUNX1 and ERG in a single chromosome (R+/+/mEt+/+/m-Tri21-
GATA1wt and -GATA1s, and R+/+/mEr+/+/m-Tri21-GATA1s), also
eliminated the accelerating effect on early hematopoiesis,
whereas single targeting of ETS2 (Et+/+/m-Tri21-GATA1wt
and -GATA1s) or ERG (Er+/+/m-Tri21-GATA1s) was insufficient
to fully cancel out this effect. This result indicated that an extra
copy of theRUNX1 gene is indispensable for the accelerated he-
matopoiesis caused by trisomy 21. RUNX1 has three major iso-
forms: RUNX1a, RUNX1b, and RUNX1c. The expression of the
RUNX1b/c isoforms was higher than that of RUNX1a in our day
8 EBs (data not shown), which is consistent with a previous study
(Real et al., 2013). Lentiviral transduction of RUNX1c into Di21-
and Partial-Tri21-GATA1wt iPSCs increased the expression of
RUNX1 to levels similar to that observed in Tri21-GATA1wt
iPSCs (Figure 6C). This enforced RUNX1 expression caused no
significant change in CD43+ cell production, whereas a slight in-
crease was observed in Partial-Tri21-GATA1wt iPSCs. This sug-
gests that the dosage effects of the additional genes may be
required for hematopoietic enhancement.
In contrast, single targeting of RUNX1 in Tri21-GATA1s
iPSCs (R+/+/m-Tri21-GATA1s) was not sufficient to decrease
the CD34+CD41+ double-positive cell population during mega-
karyocyte differentiation (Figure 6D). ERG alone (Er+/+/m-
Tri21-GATA1s) or double targeting of RUNX1 and ETS2Cell Reports 15, 1228–1241, May 10, 2016 1235
BNeo
RUNX1
PGK
loxP
pA PuroΔTKPGK
loxP
pA
~4Mb
HSA21 RUNX1 DYRK1A ERG ETS2
Ex6 Ex5 Ex4 Ex3 Ex2
TALEN target site 3
RUNT domain
microsatellite
ETS domain
TALEN target site 4
Ex9 Ex10
ETS2
Neo pAPGK
Ex6 Ex4 Ex3 Ex2
PuroΔTKPGK pA
Ex8
Ex10Ex8
Cre-loxP excision
A
1st targeting
(microsatellite analysis)
2nd targeting 
(SNP genotyping)
C
To
ta
l C
D
34
+ C
D
41
+  c
el
ls
**
Partial-Tri21-
GATA1s
0
500
1000
1500
2000
Tri21-
GATA1s
Patial-Tri21-
GATA1s
Mock LV-GATA1s
**
n.s.
n.s.
GATA1
mRNA
ACTB
mRNA
Water
Partial-Tri21-
GATA1s
Tri21-
GATA1s
Patial-Tri21-
GATA1s Mock
LV-
GATA1s
120 bp
359 bp375 bp
Wt Short
Trisomy 21
Wt Short
Partial Trisomy 21 with
4Mb deletion
359 bp 342 bp
Water
GATA1
mRNA
ACTB
mRNA
cycles
0
0.0001
0.0002
0.0003
0.0004
0.0005
Di21-
GATA1s
Tri21-
GATA1s
Partial-Tri21-
GATA1s
G
A
TA
1s
 m
R
N
A
re
la
tiv
e 
ex
pr
es
si
on
**
D
E
F
Di21-GATA1wt
DAPI
APP
DYRK1A
Tri21-GATA1wt
Partial-Tri21-GATA1wt Partial-Tri21-GATA1s
Disomy 21 Partial Trisomy 21Trisomy 21
APP
DYRK1A
2 foci
2 foci 2 foci
3 foci 3 foci
3 foci
+1
0
-1
-2
R2 R1 F3 F4
F2 F1 R3 R4
Neo pAPGK
RUNX1
Ex6
ETS2
Ex10Fwd
Rev
Tri21-GATA1wt
Figure 5. Trisomy of the 4-Mb Region on Chromosome 21 Perturbs Megakaryocyte Development via GATA1s Upregulation
(A) Schematic overview depicting the targeting strategy for the Partial-Tri21-GATA1wt iPSC line. Enlarged schemas indicate each gene locus, including exons
(gray boxes), TALEN target sites (arrows), microsatellite sequences (purple stripe), homology arms (RUNX1, orange and green bars; ETS2, pink and blue bars),
and functionally important domains (RUNX1, RUNT domain; ETS2, ETS domain) (black bars). Below are schemas of each donor plasmid including homology
arms, human PGKpromoters, drug-resistance genes (Neo or PuroDTK), poly(A) sequences, loxP sequences (red triangles), and the primers (black arrows) used in
junctional PCR analysis. PuroDTK, fusion protein of puromycin and a truncated version of herpes simplex virus type 1 thymidine kinase.
(B) Array CGH profile of the Partial-Tri21-GATA1wt iPSC line compared with Tri21-GATA1wt iPSCs. Top: complete genomic view (vertical orientation) created by
Agilent GenomicWorkbench. Bottom: expanded chromosome view (horizontal view) of the 4-Mb region. x and y axes indicate the genomic location and intensity
log2 ratio, respectively. The 4-Mb region located between RUNX1 and ETS2 is indicated by a blue-translucent rectangle.
(C) Top: semiquantitative RT-PCR analysis of GATA1s expression in sorted CD34+CD38 progenitors derived from lentivirus-transduced iPSCs on day 8.
Bottom: average CD34+CD41+ cell number per well on day 15 (n = 3 per line).
(D) Representative photomicrographs showing semiquantitative RT-PCR products for GATA1 and b-actin mRNAs in each iPSC line. The short-form product was
detected as a 120-bp band. Expected fragment sizes: Tri21-GATA1wt, 359/120 bp; Tri21-GATA1s, 375/120 bp; Partial-Tri21-GATA1wt, 359/120 bp; Partial-
Tri21-GATA1s, 342/120 bp (see also Figures 2H and 4I).
(E) Relative expression levels of GATA1s to b-actin in CD34+CD38 cells (day 8) derived from Di21-, Tri21-, and Partial-Tri21-GATA1s EBs (n = 3 per line).
(F) Fluorescence in situ hybridization of chromosome 21-specific probes for each hiPSC line. The APP gene, which is located outside the 4-Mb region, was
labeled with a green probe, while the DYRK1A gene, which is located inside and was deleted in partial trisomy 21 iPSCs, was labeled with a red probe. DAPI-
stained nuclei are in blue. Expected number of APP and DYRK1A foci in each iPSC line is shown below. Scale bars represents 10 mm.
Error bars represent SEM. Student’s t tests were used to compare Tri21-GATA1s iPSC line and the other lines. Paired t tests were used to compare between
mock- and GATA1s-transduced iPSCs. *p < 0.05, **p < 0.01. See also Figure S5.
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Figure 6. RUNX1, ETS2, and ERG Are Critical Regulators of Hematopoietic Abnormalities in Trisomy 21
(A) Schematic illustration of an additional eight types of iPSC lines. One or two candidate genes in the 4-Mb region were disrupted in a single chromosome in the
Tri21-GATA1wt or -GATA1s iPSC line (RUNX1, R+/+/m; ETS2, Et+/+/m; ERG, Er+/+/m; RUNX1 and ETS2, R+/+/mEt+/+/m; and RUNX1 and ERG, R+/+/mEr+/+/m).
(B) Percentage of CD235- and CD33-positive cells derived from day 12 EBs (n = 416 per line).
(C) Top: semiquantitative RT-PCR analysis of RUNX1 expression in sorted CD34+CD38Lin cells derived from lentivirus-transduced iPSCs on day 8. Bottom:
percentage of CD43-positive cells among CD34+CD38Lin cells derived from day 8 EBs (n = 3 per line).
(D) Average number of total CD34+CD41+ cells per well on day 15 (n = 35 per line).
(legend continued on next page)
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(R+/+/mEt+/+/m-Tri21-GATA1s) as well as RUNX1 and ERG
(R+/+/mEr+/+/m-Tri21-GATA1s) significantly decreased the gener-
ation of CD34+CD41+ megakaryoblasts. Importantly, this reduc-
tion was accompanied by decreased mRNA expression of
GATA1s (Figure 6E). Taken together, the increased gene dosage
of RUNX1, ETS2, and ERG perturbs megakaryocyte differentia-
tion synergistically via GATA1s upregulation.
Hematopoiesis is tightly controlled by numerous key tran-
scription factors that form a densely interconnected auto-regula-
tory network (Sive and Go¨ttgens, 2014; Wilson et al., 2011). The
expression levels of RUNX1, ETS2, and ERG in Tri21-GATA1wt
iPSCs were increased by 1.8-fold compared with those in
Di21-GATA1wt iPSCs, which were slightly higher than the ex-
pected change in gene dosage (i.e., 1.5-fold; data not shown).
The upregulation of these three genes was further enhanced
up to 2- to 3-fold by GATA1s in Tri21-GATA1s iPSCs (Fig-
ure S5A). It is known that GATA1, TAL1, and LYL1 are involved
in a complex combinatorial interaction network in hematopoietic
stem/progenitor cells, together with RUNX1, ETS2, and ERG
(Wilson et al., 2010). Intriguingly, mRNA expression levels of
these transcriptional factors at the early developmental stage
were markedly upregulated in Tri21-GATA1s iPSCs compared
with those in Di21-GATA1wt iPSCs (Figure 6F). The level of
expression of TAL1, a key regulator of hematopoietic gene
expression that acts as an oncogene when expressed aber-
rantly, was approximately doubled in trisomy cells and
decreased by reductions in the dosage of RUNX1, ETS2, or
ERG. The expression of both LMO2, a scaffolding protein
involved in the TAL1 complex (Ryan et al., 2008), and LYL1, a pa-
ralog of TAL1 (Curtis et al., 2012), showed similar increases in
trisomic cells and decreases by gene modification to some
extent, suggesting the presence of an interconnected circuit
involving these factors. In addition, ETO2, the transcriptional
corepressor, andMYB, an essential regulator of definitive hema-
topoiesis (Mucenski et al., 1991), were upregulated3-fold in tri-
somy 21 and returned to normal levels in RUNX1-, ETS2-, and
ERG-targeted trisomy cells. These findings imply that thesemol-
ecules are distinct targets of a dysregulated network leading to
aberrant hematopoiesis.
DISCUSSION
The pathological phenotypes of DS are likely to result from extra
copies of dosage-sensitive genes located in HSA21. Genotype/
phenotype studies in partial trisomy 21 patients suggest that
there are critical segment(s) responsible for DS pathogenesis
(commonly referred to as the Down syndrome critical region)
(Korbel et al., 2009; Lyle et al., 2009). However, no studies
have successfully determined the minimal range of the region(s)
and proved causal genotype/phenotype relationships experi-
mentally. Our cellular disease models enabled us to identify a(E) Relative expression levels of GATA1s in CD34+CD38Lincells derived from G
lines in which one or two genes were disrupted in a single chromosome (day 8; n
(F) Fold changes of the expression of hematopoietic transcription factors in CD34+
with the Di21-GATA1wt iPSC line (day 8; n = 3).
Error bars represent SEM. Student’s t tests or Mann–WhitneyU tests were used to
used to compare between mock- and RUNX1-transduced iPSCs.*p < 0.05, **p <
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matopoietic abnormalities.
Further differentiation experiments using these iPSC models
demonstrated that the hematopoietic defects in DS progress
via two steps: (1) constitutive trisomy 21 causes RUNX1-medi-
ated but GATA1-independent acceleration of early hematopoie-
sis, and (2) the acquired GATA1s mutation leads to RUNX1/
ETS2/ERG-mediated and GATA1s dose-dependent hyperprolif-
eration of aberrant megakaryoblasts in TMD.
Normal definitive hematopoiesis is maintained by the two
copies of chromosome 21 and the full-length form of GATA1
(Figure 7, left). In the first step, a one-copy gain of the RUNX1
gene to three copies plays a critical role (Figure 7, middle).
RUNX1 is essential for the emergence of HSCs from the hemo-
genic endothelium through a process called ‘‘endothelial-to-
hematopoietic transition’’ (EHT), and its deficiency leads to a
significant decrease in the numbers of hematopoietic precur-
sors (Chen et al., 2009; Lancrin et al., 2009). Our results demon-
strated a remarkably sensitive response of the generation of
CD43+ cells to only a 1.5-fold increase in the RUNX1 copy num-
ber, indicating that trisomy 21 may exert its effect on early
hematopoiesis through the acceleration of this EHT process
(Figures 3D, S6B, and S6C). The RUNX1-mediated acceleration
of early hematopoiesis expanded the HSC pool and contributed
to subsequent increases in the numbers of differentiated he-
matopoietic cells in the presence of the GATA1 full-length
form. Our lentiviral transduction experiments showed that the
enforced expression of RUNX1c induced no change in Di21-
GATA1wt iPSCs and a modest, but not significant, enhance-
ment in Partial-Tri21-GATA1wt iPSCs in terms of hematopoietic
commitment. This suggests the existence of other dosage-sen-
sitive genes both inside and outside the 4-Mb region, in addition
to the essential function of RUNX1. Coexpression experiments
of ETS2, ERG, DYRK1A, or BACH1, which are also implicated
in hematopoiesis, should be performed (Chou et al., 2012; Ma-
linge et al., 2012).
In the second step, an acquired somatic GATA1s mutation
perturbs a transcriptional network involved in the regulation of
fetal HSCs, in close synergy with trisomy 21 (Figure 7, right).
Pathogenic crosstalk between constitutive trisomy 21 and the
specific GATA1s mutation is most typically observed in mega-
karyocyte development. A recent study showed the combinato-
rial effects of trisomy 21 and GATA1s on erythrocyte and
megakaryocyte differentiation and successfully elucidated the
functional roles of the GATA1 N terminus in erythropoiesis (By-
rska-Bishop et al., 2015). Our current study confirms most of
these results and further shifts the focus to the underlying mech-
anism of the synergistic interaction between trisomy 21 and
GATA1s. Notably, we found that GATA1s expression is signifi-
cantly upregulated by trisomy 21, leading to further excessive
production of aberrant megakaryocytes.ATA1s iPSC lines. Red, Tri21-GATA1s iPSC line; light blue, Tri21-GATA1s iPSC
= 3).
CD38Lincells derived from gene-edited Tri21-GATA1s iPSC lines compared
compare Tri21-GATA1wt or -GATA1s lines and the others. Paired t tests were
0.01. See also Figure S6.
Trisomy 21 Trisomy 21
RUNX1
(2 copies)
4-Mb critical region 
Disomy 21
Normal
(Disomy 21 + GATA1wt)
Megakaryocyte
Erythrocyte Myeloid cells
GATA1
Full-length form
1st Step
(Trisomy 21 + GATA1wt)
2nd Step
(Trisomy 21 + GATA1s; TMD)
RUNX1
(3 copies)
Megakaryocyte
Erythrocyte Myeloid cells
GATA1
Full-length form
RUNX1
(3 copies)
Aberrant Megakaryoblast
Erythrocyte Myeloid cells
GATA1s
Upregulation
RUNX1/ETS2/ERG
(3 copies each)
4-Mb critical region 
Early 
Hematopoiesis
Early 
Hematopoiesis
Early 
Hematopoiesis
Figure 7. Synergistic Interactions between Trisomy 21 and GATA1 Mutation during Hematopoiesis
Normal hematopoiesis is maintained in the presence of disomy 21 and the GATA1 full-length form. Moderate expression of the two copies of the RUNX1 gene is
essential for early hematopoiesis. The GATA1 full-length form supports normal differentiation of megakaryocyte and erythrocyte lineages (disomy 21 +GATA1wt,
left). Constitutive trisomy 21 (the first step) involving a 1.5-fold increase in the RUNX1 gene dosage promotes early hematopoiesis, resulting in an expanded
hematopoietic progenitor pool and increased numbers of differentiated cells of multiple lineages (trisomy 21 + GATA1wt, middle). The GATA1 full-length form is
indispensable for normal differentiation of erythrocyte and megakaryocyte lineages, and the absence of the full-length form severely impairs erythropoiesis and
megakaryopoiesis. In addition, the GATA1 short-form mutation (the second step) causes exclusive generation of aberrant megakaryoblasts. Trisomy 21 ac-
celerates abnormal megakaryocyte differentiation through not only enhancement of early hematopoiesis but also upregulation of GATA1s expression, which is
mediated by dosage alterations in RUNX1, ETS2, and ERG (trisomy 21 + GATA1s, right).TheGATA1 protein forms a pentameric complex by interacting
with TAL1, LMO2, LDB1, and E2A, which constitutes a core tran-
scriptional circuit through direct/indirect binding to RUNX1,
ETS2, and ERG (Rainis et al., 2005; Taoudi et al., 2011). In
leukemic cells, these transcription factors form a positive feed-
forward loop (Sanda et al., 2012), and even a subtle increase in
the gene dosage of some network members on HSA21 (i.e.,
RUNX1, ETS2, and ERG) can upregulate the entire network
and robustly activate the key target molecules RUNX1 and
GATA1s by up to nearly 3-fold. Increased expression of GATA1s
enhances the generation of aberrant megakaryocytes in a dose-
dependent manner, and the expansion of the CD43+ progenitor
pool, which is stimulated by RUNX1, further accelerates this
abnormal differentiation. Intriguingly, the proportion of CD43+
progenitor cells (as well as the generation of subsequent
CD235+ cells and CD33+ cells) was even smaller in the Partial-
Tri21-GATA1wt iPSC line than in the Di21-GATA1wt iPSC line
(Figures 6B and S6B). Similarly, the double-positive CD34+
CD41+ cell population was smaller in the Partial-Tri21-GATA1s
iPSC line than in the Di21-GATA1s iPSC line (Figure S5J), which
was accompanied by lower GATA1s expression (Figure 5E).
These observations indicate that there may be an additional
key molecule that functions as a suppressor of the hemato-
poietic transcriptional network outside the 4-Mb region.
In addition to TMD andML-DS, neonatal DS patientsmay have
a variety of hematological abnormalities such as neutrophilia and
polycythemia (Choi, 2008; Henry et al., 2007). The data obtained
in the present study are consistent with these DS symptoms and
provide an explanation for the clinical findings by suggesting
possible causative factors in HSA21 and cross-regulatory inter-
actions between aneuploidy and specific gene mutations. Our
results suggest that many pathological features observed inDS are caused not by the simple summation of individual
gene-dosage effects but by the complex orchestration of critical
regulators. Our collection and engineering of DS-derived iPSC
lines will provide an unprecedented experimental platform for
detailed comparative analyses of this multi-step andmulti-facto-
rial disease process and may contribute to the development of
new therapies.
EXPERIMENTAL PROCEDURES
Full details are provided in the Supplemental Experimental Procedures.
Generation of Human iPSCs
Induced pluripotent stem cells (iPSCs) were generated using a Sendai virus
(SeV) vector encoding tetracistronic factors (OCT4, SOX2, KLF4, and
c-MYC) with the miR-302 target sequence (SeVp [KOSM302L]) as described
previously (Nishimura et al., 2011).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and seven tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.04.031.
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